Centurium considers stake sale in US$6 billion Taibang Biologic: sources

Chinese private equity firm Centurium Capital is considering selling its stake in Taibang Biologic Group, people familiar with the matter said.

Centurium has been sounding out potential buyers, including state-owned entities, according to the people, who asked not to be identified because the deliberations are private.

A transaction could value the Chinese biopharmaceutical company at about US$6 billion, the people said.

Considerations are ongoing and no final decision has been made on whether to proceed with a sale, the people added.

A representative for Centurium declined to comment. Taibang did not respond to a request for comment.

Founded in 2002 and previously known as China Biologic Products Holdings, Taibang was listed in New York from 2009 until a US$4.8 billion take-private deal in 2021. The company then looked to list in Hong Kong, Bloomberg News reported in 2022.

SEE ALSO

The Hong Kong share sale did not materialise, but Taibang raised US$300 million in 2022 from investors including Abu Dhabi Investment Authority subsidiary Platinum Orchid and Singaporean sovereign wealth fund GIC.

Taibang develops plasma-based biopharmaceutical products in three main categories: albumin, human immunoglobulin and human coagulation factors, its website shows.

The take-private deal in 2021 involved a consortium led by Centurium, and which also included Citic Capital, Hillhouse and Temasek Holdings.